Seedlabs

SLC25A45-Based Metabolic Biomarker Panel

A diagnostic blood test to measure SLC25A45 mutation status and methylated amino acid levels to predict patient response to GLP-1 receptor agonist (GLP-1RA) weight-loss drugs.

Biochemistry, Genetics and Molecular BiologyMetabolism and Genetic Disorders
Pharmaceutical companies producing GLP-1RAs (e.g., Novo Nordisk, Eli Lilly) can use this to improve clinical trial success rates and patient outcomes by screening for metabolic compatibility.
Try the live prototype
slc25a45-based-61ca.seedlabs.tech
Open

Concept

A clinical diagnostic tool that screens for the R285C mutation in SLC25A45 and measures the concentration of methylated amino acids (like trimethyllysine) in human plasma. This panel would serve as a companion diagnostic for clinicians prescribing GLP-1RA therapies, identifying 'non-responders' who may be resistant to adipose tissue loss due to impaired carnitine biosynthesis and faulty fuel switching.

Why now

Research shows that SLC25A45 is essential for the mitochondrial uptake of methylated amino acids and the biosynthesis of carnitine [0]. Crucially, deficiency in this carrier renders subjects resistant to lipid mobilization by GLP-1RA, meaning some patients may not lose weight on these drugs because they cannot effectively switch their fuel source to fatty acid oxidation [1].

AI assessment

Backed by 2 papers94

A high-potential companion diagnostic that leverages a specific genetic and metabolic mechanism to solve the 'non-responder' problem in the massive GLP-1RA market.

Evidence strength
5/5
The idea is directly supported by two converging findings: one identifying the specific carrier (SLC25A45) and mutation (R285C), and another explicitly linking its deficiency to GLP-1RA resistance in vivo.
Market pull
5/5
Pharmaceutical giants like Novo Nordisk and Eli Lilly have a massive financial incentive to reduce trial failure rates and improve real-world efficacy for their blockbuster weight-loss drugs.
Novelty & moat
4/5
While genetic testing is common, targeting this specific mitochondrial carrier for GLP-1RA response is a novel application of recent basic science.
Feasibility
4/5
The MVP consists of a standard genetic assay for the R285C mutation and a mass spectrometry-based plasma panel for methylated amino acids, both of which are technically mature.
Wedge clarity
5/5
The wedge is extremely sharp: a single diagnostic panel to identify non-responders to a specific class of high-demand drugs.
Simplicity / focus
5/5
The product is a focused diagnostic test with a clear utility, avoiding the trap of building a broad metabolic platform.

Scored by AI against a fixed rubric (evidence, market, novelty, feasibility, wedge, simplicity). A prior estimate to compare ideas before real-world signal arrives.

Who benefits

  • Endocrinologistsindividual

    Allows them to identify biological reasons for treatment failure in obese patients rather than attributing it to patient non-compliance.

  • Pharmaceutical Companiescompany

    Reduces the 'noise' in clinical trials by excluding patients with SLC25A45 deficiencies who are biologically resistant to the drug's lipid-mobilizing effects.

  • GLP-1RA Manufacturerscompany

    Reduces the perceived failure rate of their drugs by filtering out biologically resistant populations.

Research it builds on

  1. SLC25A45 is required for mitochondrial uptake of methylated amino acids and de novo carnitine biosynthesis
    Marília M. Dias, Martin King, Engy Shokry et al. · 2025 · 10 citations
  2. Mitochondrial control of fuel switching via carnitine biosynthesis
    Christopher Auger, Hiroshi Nishida, Bo Yuan et al. · 2026 · 7 citations
Leave feedback
feasibility